Not yet in the clin­ic, Beam’s base-edit­ed, off-the-shelf CAR-T put on hold

3 years ago
R&D
Cell/Gene Tx

David Hung's Nu­va­tion Bio ax­es clin­i­cal pro­gram, lays off 30 af­ter re­searchers say they can't man­age the side ef­fects

3 years ago
People
R&D

Pos­i­tive PhI­II re­sults in hand, Con­cert Phar­ma forges ahead with NDA and com­mer­cial­iza­tion plans for hair loss drug

3 years ago
R&D

San Diego biotech fails PhII in ear-ring­ing and will cut costs in pipeline prun­ing

3 years ago
R&D

Re­gen­eron ends four clin­i­cal tri­als of its rolled-back Covid-19 an­ti­body

3 years ago
R&D
Pharma

Ipsen jumps in­to the TCR space, team­ing with start­up helmed by for­mer Mer­ck KGaA can­cer chief

3 years ago
Deals

As­traZeneca cuts PhI­II tri­al short af­ter next-gen check­point drug fails in­ter­im analy­sis

3 years ago
R&D

Af­ter Roe, star­tups seek to fill Big Phar­ma’s male con­tra­cep­tion gap

3 years ago
Startups
In Focus

Big Phar­ma's in­creas­ing M&A en­thu­si­asm; Manchin, Schumer reach deal on drug pric­ing; Earn­ings re­caps; and more

3 years ago
Weekly

Ar­cutis pulls in a win for its top­i­cal ver­sion of an old As­traZeneca drug in plaque pso­ri­a­sis

3 years ago
Pharma
FDA+

Ab­b­Vie, No­vo Nordisk TV ads gen­er­ate most search­es in first half of 2022, ad track­er finds

3 years ago
Pharma
Marketing

CEO Pas­cal So­ri­ot says As­traZeneca is grow­ing 'new branch­es' as Covid vac­cine sales con­tin­ue to fall

3 years ago
Pharma

JA­MA study finds can­cer drug da­ta is still large­ly un­avail­able to qual­i­fied re­searchers

3 years ago
Pharma

Which drugs may be hit with ne­go­ti­a­tions if the rec­on­cil­i­a­tion bill pass­es? Wall St. an­a­lysts ex­plain

3 years ago
Pharma
Law

Ab­b­Vie stays bull­ish on fu­ture per­for­mance as Skyrizi con­tin­ues to im­press — but 'price con­trol­s' would be a game ...

3 years ago
Pharma

Trans­plant Games kick off in San Diego, rais­ing or­gan do­na­tion aware­ness, com­mu­ni­ty and hope

3 years ago
Pharma
Marketing

More dra­ma ahead: Sarep­ta plans to file for ac­cel­er­at­ed Duchenne ap­proval, with ad­comm a 'n­ear cer­tain­ty'

3 years ago
R&D

Covid-19 roundup: Mod­er­na, US sign con­tract for au­tumn boost­er dos­es; Enan­ta touts PhI re­sults for its an­tivi­ral

3 years ago
Coronavirus

Icosavax dis­cov­ers what caused its lead vac­cine to flop, and does­n't see it af­fect­ing fol­low-up pro­grams

3 years ago
R&D

Bris­tol My­er­s' com­bo hits a road­block in PhI­II kid­ney test as the search to ri­val Keytru­da con­tin­ues

3 years ago
R&D
Pharma

Af­ter near­ly a decade of work, As­traZeneca ax­es WEE1 and culls Mod­er­na-part­nered drug

3 years ago
R&D
Pharma

Seagen stays qui­et on M&A as it push­es Keytru­da-Pad­cev com­bo, con­tin­ues CEO search

3 years ago
Pharma

Ex­clu­sive: UPMC launch­es an­oth­er biotech, root­ed in the tu­mor mi­croen­vi­ron­ment

3 years ago
Financing
Startups

Tonix will test its mon­key­pox vac­cine in Kenya next year, and no eyes on ac­cel­er­at­ed path at FDA

3 years ago
R&D
Coronavirus
First page Previous page 487488489490491492493 Next page Last page
A service from the Financial Times